Summary Box: Vertex's hep C drug Incivek approved
CLEARANCE: Vertex Pharmaceuticals Inc.'s hepatitis C drug Incivek received marketing approval Monday, about a week after the Food and Drug Administration approved a competing pill.
NEW ENTRY: Incivek and Merck and Co.'s Victrelis are both are taken three times a day as part of a drug cocktail, and they are significantly more effective than older drugs at curing hepatitis C, a chronic disease of the liver. Standard therapies cure less than half of all patients.
PRICE: Vertex says a 12-week course of Incivek treatment will cost $49,200, although it is offering financial support for some patients.